OA12126A - Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune,and respiratory diseases. - Google Patents
Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune,and respiratory diseases. Download PDFInfo
- Publication number
- OA12126A OA12126A OA1200200193A OA1200200193A OA12126A OA 12126 A OA12126 A OA 12126A OA 1200200193 A OA1200200193 A OA 1200200193A OA 1200200193 A OA1200200193 A OA 1200200193A OA 12126 A OA12126 A OA 12126A
- Authority
- OA
- OAPI
- Prior art keywords
- compound
- ureido
- substituted
- compound according
- methoxy
- Prior art date
Links
- 208000023275 Autoimmune disease Diseases 0.000 title abstract 2
- 108010008212 Integrin alpha4beta1 Proteins 0.000 title abstract 2
- 230000001363 autoimmune Effects 0.000 title abstract 2
- 208000027866 inflammatory disease Diseases 0.000 title abstract 2
- 230000002757 inflammatory effect Effects 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 208000023504 respiratory system disease Diseases 0.000 title abstract 2
- 230000001419 dependent effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 54
- 239000000651 prodrug Chemical class 0.000 claims abstract 2
- 229940002612 prodrug Drugs 0.000 claims abstract 2
- 150000003839 salts Chemical class 0.000 claims abstract 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 15
- 229940095574 propionic acid Drugs 0.000 claims 15
- 125000000217 alkyl group Chemical group 0.000 claims 10
- 125000003118 aryl group Chemical group 0.000 claims 8
- 125000001072 heteroaryl group Chemical group 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 239000001257 hydrogen Substances 0.000 claims 7
- 125000000623 heterocyclic group Chemical group 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 239000002253 acid Substances 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 2
- 229910014585 C2-Ce Inorganic materials 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 101100379079 Emericella variicolor andA gene Proteins 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- SGPGESCZOCHFCL-UHFFFAOYSA-N Tilisolol hydrochloride Chemical compound [Cl-].C1=CC=C2C(=O)N(C)C=C(OCC(O)C[NH2+]C(C)(C)C)C2=C1 SGPGESCZOCHFCL-UHFFFAOYSA-N 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 claims 1
- 125000002837 carbocyclic group Chemical group 0.000 claims 1
- 150000001721 carbon Chemical group 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 125000001151 peptidyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C311/06—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/14—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17326099P | 1999-12-28 | 1999-12-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| OA12126A true OA12126A (en) | 2006-05-05 |
Family
ID=22631221
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| OA1200200193A OA12126A (en) | 1999-12-28 | 2000-12-15 | Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune,and respiratory diseases. |
Country Status (35)
| Country | Link |
|---|---|
| US (4) | US20020049236A1 (fr) |
| EP (1) | EP1244656A1 (fr) |
| JP (1) | JP2003519697A (fr) |
| KR (1) | KR20020067050A (fr) |
| CN (1) | CN1413210A (fr) |
| AP (1) | AP2002002565A0 (fr) |
| AR (1) | AR029216A1 (fr) |
| AU (1) | AU2018301A (fr) |
| BG (1) | BG106867A (fr) |
| BR (1) | BR0016818A (fr) |
| CA (1) | CA2396087A1 (fr) |
| CO (1) | CO5261616A1 (fr) |
| CR (1) | CR6682A (fr) |
| CZ (1) | CZ20022072A3 (fr) |
| EA (1) | EA004673B1 (fr) |
| EE (1) | EE200200372A (fr) |
| GT (1) | GT200000226A (fr) |
| HU (1) | HUP0203897A3 (fr) |
| IL (1) | IL149758A0 (fr) |
| IS (1) | IS6382A (fr) |
| MA (1) | MA26861A1 (fr) |
| NO (1) | NO20023085L (fr) |
| NZ (1) | NZ518886A (fr) |
| OA (1) | OA12126A (fr) |
| PA (1) | PA8509301A1 (fr) |
| PE (1) | PE20010987A1 (fr) |
| PL (1) | PL357109A1 (fr) |
| SK (1) | SK8692002A3 (fr) |
| SV (1) | SV2002000246A (fr) |
| TN (1) | TNSN00256A1 (fr) |
| TR (1) | TR200201668T2 (fr) |
| UY (1) | UY26512A1 (fr) |
| WO (1) | WO2001051487A1 (fr) |
| YU (1) | YU41202A (fr) |
| ZA (1) | ZA200205142B (fr) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003519697A (ja) * | 1999-12-28 | 2003-06-24 | ファイザー・プロダクツ・インク | 炎症性疾患、自己免疫疾患および呼吸器疾患の処置に有用な非ペプチド系のｖｌａ−４依存性細胞結合阻害薬 |
| US6960597B2 (en) * | 2000-06-30 | 2005-11-01 | Orth-Mcneil Pharmaceutical, Inc. | Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists |
| EP1346982B1 (fr) * | 2000-12-28 | 2011-09-14 | Daiichi Pharmaceutical Co., Ltd. | Inhibiteurs de vla-4 |
| US7273889B2 (en) * | 2002-09-25 | 2007-09-25 | Innovative Drug Delivery Systems, Inc. | NMDA receptor antagonist formulation with reduced neurotoxicity |
| JP2006520796A (ja) * | 2003-03-17 | 2006-09-14 | タケダ サン ディエゴ インコーポレイテッド | ヒストンデアセチラーゼインヒビター |
| CA2770493A1 (fr) | 2003-07-24 | 2005-02-03 | Daiichi Pharmaceutical Co., Ltd. | Compose acide cyclohexanecarboxylique |
| US20050176755A1 (en) * | 2003-10-31 | 2005-08-11 | Dyatkin Alexey B. | Aza-bridged-bicyclic amino acid derivatives as alpha4 integrin antagonists |
| BRPI0506676A (pt) * | 2004-02-10 | 2007-05-15 | Janssen Phamaceutica N V | piridazinona uréias como antagonistas de integrinas alfa4 |
| JP2007522225A (ja) * | 2004-02-10 | 2007-08-09 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Ａ４インテグリン拮抗薬としてのピリダジノン |
| TW200610754A (en) * | 2004-06-14 | 2006-04-01 | Daiichi Seiyaku Co | Vla-4 inhibitor |
| US7453002B2 (en) * | 2004-06-15 | 2008-11-18 | Bristol-Myers Squibb Company | Five-membered heterocycles useful as serine protease inhibitors |
| CA2583267A1 (fr) * | 2004-10-12 | 2006-04-27 | Amgen Inc. | Nouveaux antagonistes des recepteurs de la bradykinine b1 |
| US20070042049A1 (en) * | 2005-06-03 | 2007-02-22 | Elan Pharma International, Limited | Nanoparticulate benidipine compositions |
| CA2611319A1 (fr) * | 2005-06-07 | 2006-12-14 | William F. Degrado | Inhibiteurs d'integrine .alpha.2.beta.1/gpia-iia |
| US8987306B2 (en) * | 2005-06-07 | 2015-03-24 | The Trustees Of The University Of Pennsylvania | Inhibitors of integrin alpha2beta1 based on prolyl diaminopropionic acid scaffold |
| WO2007069635A1 (fr) | 2005-12-13 | 2007-06-21 | Daiichi Sankyo Company, Limited | Médicament inhibiteur de vla-4 |
| AU2006337137B2 (en) | 2005-12-29 | 2012-06-14 | Tersera Therapeutics Llc | Multicyclic amino acid derivatives and methods of their use |
| EP2510941A3 (fr) | 2007-02-20 | 2013-01-23 | Merrimack Pharmaceuticals, Inc. | Procédés de traitement de la sclérose en plaques par administration d'une alpha-foetoprotéine combinée à un antagoniste de l'intégrine |
| US8012886B2 (en) * | 2007-03-07 | 2011-09-06 | Asm Assembly Materials Ltd | Leadframe treatment for enhancing adhesion of encapsulant thereto |
| EP2860260A1 (fr) | 2008-04-11 | 2015-04-15 | Merrimack Pharmaceuticals, Inc. | Lieurs d'albumine de sérum humain et de leurs conjugués |
| CN102282168A (zh) * | 2008-11-18 | 2011-12-14 | 梅里麦克制药股份有限公司 | 人血清白蛋白接头以及其结合物 |
| EP2467159A1 (fr) | 2009-08-20 | 2012-06-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Vla-4 en tant que biomarqueur pour le pronostic et le ciblage pour thérapie dans la dystrophie musculaire de duchenne |
| EP3326645B1 (fr) | 2010-10-25 | 2020-03-18 | Biogen MA Inc. | Procédés de détermination de différences dans l'activité alpha-4 intégrine par la corrélation de différences des taux de svcam et/ou de smadcam |
| JP5971657B2 (ja) * | 2011-04-20 | 2016-08-17 | 塩野義製薬株式会社 | Ｔｒｐｖ４阻害活性を有する芳香族複素環誘導体 |
| AU2012272898A1 (en) | 2011-06-24 | 2013-04-11 | Amgen Inc. | TRPM8 antagonists and their use in treatments |
| US8710043B2 (en) | 2011-06-24 | 2014-04-29 | Amgen Inc. | TRPM8 antagonists and their use in treatments |
| CN102268067A (zh) * | 2011-06-29 | 2011-12-07 | 河北师范大学 | 一种含ldv序列短肽的聚乙二醇化衍生物 |
| BR112014009144A8 (pt) | 2011-10-17 | 2017-06-20 | Univ Muenster Westfaelische Wilhelms | avaliação do risco de pml e métodos com base na mesma |
| KR101699822B1 (ko) | 2011-12-21 | 2017-01-25 | 노비라 테라퓨틱스, 인코포레이티드 | B형 간염의 항바이러스성 제제 |
| US8952009B2 (en) | 2012-08-06 | 2015-02-10 | Amgen Inc. | Chroman derivatives as TRPM8 inhibitors |
| AR092270A1 (es) | 2012-08-28 | 2015-04-08 | Janssen R&D Ireland | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b |
| US20150202287A1 (en) | 2012-08-30 | 2015-07-23 | Merrimack Pharmaceuticals, Inc. | Combination therapies comprising anti-erbb3 agents |
| PT2961732T (pt) | 2013-02-28 | 2017-06-26 | Janssen Sciences Ireland Uc | Sulfamoil-arilamidas e utilização das mesmas como medicamentos para o tratamento de hepatite b |
| EA027068B1 (ru) | 2013-04-03 | 2017-06-30 | Янссен Сайенсиз Айрлэнд Юси | Производные n-фенилкарбоксамида и их применение в качестве лекарственных препаратов для лечения гепатита b |
| JP6441315B2 (ja) | 2013-05-17 | 2018-12-19 | ヤンセン・サイエンシズ・アイルランド・ユーシー | スルファモイルチオフェンアミド誘導体およびｂ型肝炎を治療するための医薬品としてのその使用 |
| JO3603B1 (ar) | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي |
| US10450270B2 (en) | 2013-07-25 | 2019-10-22 | Janssen Sciences Ireland Uc | Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
| MX368158B (es) | 2013-10-23 | 2019-09-20 | Janssen Sciences Ireland Uc | Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b. |
| US10392349B2 (en) | 2014-01-16 | 2019-08-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| US9169212B2 (en) | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| MX2016009449A (es) | 2014-02-05 | 2016-10-13 | Novira Therapeutics Inc | Terapia de combinacion para el tratamiento de infecciones por virus de la hepatitis b (vhb). |
| EA035848B1 (ru) | 2014-02-06 | 2020-08-20 | Янссен Сайенсиз Айрлэнд Юси | Производные сульфамоилпирроламида и их применение в качестве медикаментов для лечения гепатита b |
| EP3160508B1 (fr) * | 2014-06-30 | 2020-08-05 | The UAB Research Foundation | Nouveaux composés rexinoïde et procédés d'utilisation de composés rexinoïde pour le traitement de troubles métaboliques et du cancer |
| WO2016149581A1 (fr) | 2015-03-19 | 2016-09-22 | Novira Therapeutics, Inc. | Dérivés d'azocane et d'azonane, et méthodes de traitement d'infections provoquées par le virus de l'hépatite b |
| US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
| AU2016330964B2 (en) | 2015-09-29 | 2021-04-01 | Novira Therapeutics, Inc. | Crystalline forms of a hepatitis B antiviral agent |
| SG11201808949SA (en) | 2016-04-15 | 2018-11-29 | Novira Therapeutics Inc | Combinations and methods comprising a capsid assembly inhibitor |
| CA3090125A1 (fr) | 2018-03-14 | 2019-09-19 | Janssen Sciences Ireland Unlimited Company | Schema posologique de modulateur d'assemblage de capside |
| EP3810085A1 (fr) | 2018-06-20 | 2021-04-28 | Progenity, Inc. | Traitement d'une maladie du tractus gastro-intestinal par un inhibiteur de l'intégrine |
| US11096931B2 (en) | 2019-02-22 | 2021-08-24 | Janssen Sciences Ireland Unlimited Company | Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases |
| EP3966205A1 (fr) | 2019-05-06 | 2022-03-16 | Janssen Sciences Ireland Unlimited Company | Dérivés d'amide utiles dans le traitement d'une infection par le virus de l'hépatite b ou de maladies induites par le virus de l'hépatite b |
| WO2022162164A1 (fr) | 2021-01-29 | 2022-08-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Procedes d'évaluation du risque de développement d'une leuco-entéphalopathie multifocale progressive chez les patients traités par des antagonistes de la vla-4 |
Family Cites Families (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5192746A (en) | 1990-07-09 | 1993-03-09 | Tanabe Seiyaku Co., Ltd. | Cyclic cell adhesion modulation compounds |
| US5294713A (en) | 1991-08-23 | 1994-03-15 | Takeda Chemical Industries, Ltd. | 2-piperazinone compounds and their use |
| AU693143B2 (en) | 1993-12-06 | 1998-06-25 | Cytel Corporation | CS-1 peptidomimetics, compositions and methods of using the same |
| US5821231A (en) | 1993-12-06 | 1998-10-13 | Cytel Corporation | CS-1 peptidomimetics, compositions and methods of using same |
| US5936065A (en) | 1993-12-06 | 1999-08-10 | Cytel Corporation | CS-1 peptidomimetics, compositions and methods of using the same |
| CA2193828A1 (fr) | 1994-06-29 | 1996-01-11 | Timothy P. Kogan | Procede permettant d'inhiber la fixation de l'integrine alpha 4 beta 1 a la molecule d'adherence cellulaire vasculaire 1 ou a la fibronectine |
| ATE237342T1 (de) | 1994-07-11 | 2003-05-15 | Athena Neurosciences Inc | Inhibitoren der leukozytenadhäsion |
| US5811391A (en) | 1994-08-25 | 1998-09-22 | Cytel Corporation | Cyclic CS-1 peptidomimetics, compositions and methods of using same |
| GB9524630D0 (en) | 1994-12-24 | 1996-01-31 | Zeneca Ltd | Chemical compounds |
| US6306840B1 (en) * | 1995-01-23 | 2001-10-23 | Biogen, Inc. | Cell adhesion inhibitors |
| IL118325A0 (en) * | 1995-05-25 | 1996-10-31 | Pont Merck And Pharmaceutical | Integrin receptor antagonists and pharmaceutical compositions containing them |
| WO1996040781A1 (fr) | 1995-06-07 | 1996-12-19 | Tanabe Seiyaku Co., Ltd. | INHIBITEURS PEPTIDIQUES CYCLIQUES D'ADHERENCE CELLULAIRE INDUITE PAR INTEGRINE β1 ET β¿2? |
| EP0842195A1 (fr) | 1995-07-06 | 1998-05-20 | Zeneca Limited | Inhibiteurs peptidiques de la fibronectine |
| US6248713B1 (en) * | 1995-07-11 | 2001-06-19 | Biogen, Inc. | Cell adhesion inhibitors |
| GB9613112D0 (en) | 1996-06-21 | 1996-08-28 | Zeneca Ltd | Chemical compounds |
| AU3738597A (en) * | 1996-07-25 | 1998-02-20 | Biogen, Inc. | Molecular model for vla-4 inhibitors |
| DE19647381A1 (de) | 1996-11-15 | 1998-05-20 | Hoechst Ag | Neue Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten |
| PL323130A1 (en) | 1996-11-15 | 1998-05-25 | Hoechst Ag | Application of heterocyclic compounds in production of a pharmaceutic agent, novel heterocyclic compounds and pharmaceutic agent as such |
| DE19647380A1 (de) | 1996-11-15 | 1998-05-20 | Hoechst Ag | 5-Ring-Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten |
| WO1998042656A1 (fr) | 1997-03-21 | 1998-10-01 | Cytel Corporation | Nouveaux composes |
| DE69833654T2 (de) | 1997-05-29 | 2006-12-14 | Merck & Co., Inc. (A New Jersey Corp.) | Biarylalkansäuren in der verwendung als zelladhäsionsinhibitoren |
| JP2002501537A (ja) | 1997-05-29 | 2002-01-15 | メルク エンド カンパニー インコーポレーテッド | 細胞接着阻害薬としてのスルホンアミド類 |
| CA2291778A1 (fr) | 1997-05-29 | 1998-12-03 | Merck & Co., Inc. | Composes d'amide heterocycliques utilises en tant qu'inhibiteurs de l'adhesion cellulaire |
| US6093696A (en) | 1997-05-30 | 2000-07-25 | Celltech Therapeutics, Limited | Tyrosine derivatives |
| AU8163398A (en) | 1997-06-23 | 1999-01-04 | Pharmacia & Upjohn Company | Inhibitors of alpha4beta1mediated cell adhesion |
| AR016133A1 (es) | 1997-07-31 | 2001-06-20 | Wyeth Corp | Compuesto de carbamiloxi que inhiben la adhesion de leucocitos mediada por vla-4, compuestos que son prodrogas de dichos compuestos, composicionfarmaceutica, metodo para fijar vla-4 a una muestra biologica, metodo para el tratamiento de una condicion inflamatoria |
| CN1265672A (zh) | 1997-07-31 | 2000-09-06 | 伊兰药品公司 | 能抑制由vla－4介导的白细胞粘连的磺酰化二肽化合物 |
| WO1999006433A1 (fr) | 1997-07-31 | 1999-02-11 | Elan Pharmaceuticals, Inc. | Composes inhibant l'adhesion leucocytaire induite par vla-4 |
| EP0994895A1 (fr) | 1997-07-31 | 2000-04-26 | Elan Pharmaceuticals, Inc. | Composes de dipeptides inhibant une adhesion de leucocytes regulee par vla-4 |
| JP2001512134A (ja) | 1997-07-31 | 2001-08-21 | エラン・ファーマシューティカルズ・インコーポレーテッド | Ｖｌａ−４仲介性白血球付着を阻害する置換フェニルアラニン型化合物 |
| JP2003517424A (ja) | 1997-07-31 | 2003-05-27 | エラン・ファーマシューティカルズ・インコーポレーテッド | Ｖｌａ−４が介在する白血球接着を阻害する４−アミノ−フェニルアラニン型化合物 |
| KR20010022413A (ko) | 1997-07-31 | 2001-03-15 | 진 엠. 듀발 | Ｖｌａ-4에 의해 매개되는 백혈구 부착을 억제하는 벤질화합물 |
| WO1999006432A1 (fr) | 1997-07-31 | 1999-02-11 | Elan Pharmaceuticals, Inc. | Composes de dipeptides et associes inhibant une adhesion de leucocytes regulee par vla-4 |
| EP1005446B1 (fr) | 1997-08-22 | 2004-02-25 | F. Hoffmann-La Roche Ag | Derives de la n-aroylphenylananine |
| CA2301377C (fr) | 1997-08-22 | 2009-10-06 | F. Hoffmann-La Roche Ag | Derives de n-alcanoylphenilalanine |
| DE19741235A1 (de) | 1997-09-18 | 1999-03-25 | Hoechst Marion Roussel De Gmbh | Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| DE19741873A1 (de) | 1997-09-23 | 1999-03-25 | Hoechst Marion Roussel De Gmbh | Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| WO1999020272A1 (fr) | 1997-10-21 | 1999-04-29 | Merck & Co., Inc. | Acides azapeptidiques utilises comme inhibiteurs de l'adhesion cellulaire |
| JP4555468B2 (ja) * | 1997-10-31 | 2010-09-29 | アベンテイス・フアルマ・リミテツド | 置換アニリド |
| GB9723789D0 (en) | 1997-11-12 | 1998-01-07 | Zeneca Ltd | Chemical compounds |
| WO1999025685A1 (fr) * | 1997-11-18 | 1999-05-27 | Merck & Co., Inc. | Derives de 4-piperidine carboxamides 4-substitues |
| DE19751251A1 (de) | 1997-11-19 | 1999-05-20 | Hoechst Marion Roussel De Gmbh | Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate |
| AU1411499A (en) | 1997-11-20 | 1999-06-15 | Merck & Co., Inc. | Para-aminomethylaryl carboxamide derivatives |
| WO1999026922A1 (fr) | 1997-11-21 | 1999-06-03 | Merck & Co., Inc. | Derives de pyrrole a substitution tenant lieu d'inhibiteurs d'adhesion cellulaire |
| AU750175B2 (en) | 1997-11-24 | 2002-07-11 | Merck & Co., Inc. | Cyclic amino acid derivatives as cell adhesion inhibitors |
| CA2309341A1 (fr) | 1997-11-24 | 1999-06-03 | Merck & Co., Inc. | Derives d'alanine-.beta. agissant en tant qu'inhibiteurs de l'adhesion cellulaire |
| ATE289991T1 (de) * | 1997-12-23 | 2005-03-15 | Aventis Pharma Ltd | Substituierte beta-alaninen |
| US6197794B1 (en) | 1998-01-08 | 2001-03-06 | Celltech Therapeutics Limited | Phenylalanine derivatives |
| MY153569A (en) | 1998-01-20 | 2015-02-27 | Mitsubishi Tanabe Pharma Corp | Inhibitors of ?4 mediated cell adhesion |
| BR9907733A (pt) * | 1998-01-23 | 2000-10-17 | Novartis Ag | Antagonistas vla-4 |
| US6329372B1 (en) | 1998-01-27 | 2001-12-11 | Celltech Therapeutics Limited | Phenylalanine derivatives |
| ATE273273T1 (de) | 1998-02-26 | 2004-08-15 | Celltech Therapeutics Ltd | Phenylalaninderivate als inhibitoren von alpha4 integrinen |
| GB9805655D0 (en) | 1998-03-16 | 1998-05-13 | Celltech Therapeutics Ltd | Chemical compounds |
| US6521626B1 (en) | 1998-03-24 | 2003-02-18 | Celltech R&D Limited | Thiocarboxamide derivatives |
| KR20010087125A (ko) | 1998-04-16 | 2001-09-15 | 데이비드 비. 맥윌리암스 | 인테그린 수용체에 대한 인테그린의 결합을 억제하는 화합물 |
| WO1999054321A1 (fr) | 1998-04-21 | 1999-10-28 | Aventis Pharma Limited | Diamines substituees et leur utilisation en tant qu'inhibiteurs d'adhesion cellulaire |
| DE19821483A1 (de) | 1998-05-14 | 1999-11-18 | Hoechst Marion Roussel De Gmbh | Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| GB9811159D0 (en) | 1998-05-22 | 1998-07-22 | Celltech Therapeutics Ltd | Chemical compounds |
| SI1082302T1 (en) | 1998-05-28 | 2004-06-30 | Biogen, Inc. | A vla-4 inhibitor: omepupa-v |
| GB9811969D0 (en) | 1998-06-03 | 1998-07-29 | Celltech Therapeutics Ltd | Chemical compounds |
| GB9812088D0 (en) | 1998-06-05 | 1998-08-05 | Celltech Therapeutics Ltd | Chemical compounds |
| WO1999064395A1 (fr) | 1998-06-11 | 1999-12-16 | Merck & Co., Inc. | Composes d'amide heterocycliques utilises comme inhibiteurs d'adhesion cellulaire |
| TW591026B (en) | 1998-06-23 | 2004-06-11 | Upjohn Co | Inhibitors of alpha4beta1 mediated cell adhesion |
| TR200003848T2 (tr) * | 1998-06-30 | 2001-06-21 | Pfizer Products Inc. | VLA-4'e bağlı hücre bağlanmasının peptidil olmayan önleyicileri. |
| GB9814414D0 (en) | 1998-07-03 | 1998-09-02 | Celltech Therapeutics Ltd | Chemical compounds |
| AU1915399A (en) | 1998-07-10 | 2000-02-01 | Cytel Corporation | Cs-1 peptidomimetics, compositions and methods of using the same |
| GB9916374D0 (en) | 1998-07-23 | 1999-09-15 | Zeneca Ltd | Chemical compounds |
| AU5052199A (en) | 1998-07-23 | 2000-02-14 | Astrazeneca Ab | Chemical compounds |
| DE69934238T2 (de) | 1998-08-26 | 2007-06-21 | Aventis Pharma Ltd., West Malling | Azabicyclo-verbindungen welche die inhibition der zell adhesion modulieren |
| GB9821061D0 (en) | 1998-09-28 | 1998-11-18 | Celltech Therapeutics Ltd | Chemical compounds |
| GB9821222D0 (en) | 1998-09-30 | 1998-11-25 | Celltech Therapeutics Ltd | Chemical compounds |
| GB9821406D0 (en) | 1998-10-01 | 1998-11-25 | Celltech Therapeutics Ltd | Chemical compounds |
| GB9826174D0 (en) | 1998-11-30 | 1999-01-20 | Celltech Therapeutics Ltd | Chemical compounds |
| CA2351464A1 (fr) | 1998-12-14 | 2000-06-22 | Joan E. Sabalski | Derives de 3,4-diamino-3-cyclobutene-1,2-dione presentant une adherence aux leucocytes ayant pour origine vla-4 |
| GB9828074D0 (en) | 1998-12-18 | 1999-02-17 | Glaxo Group Ltd | Therapeutically useful compounds |
| WO2000043369A1 (fr) | 1999-01-22 | 2000-07-27 | Elan Pharmaceuticals, Inc. | Composes inhibant l'adhesion aux leucocytes a mediation assuree par vla-4 |
| AR035476A1 (es) | 1999-01-22 | 2004-06-02 | Elan Pharm Inc | Compuestos heteroarilo y heterociclicos con anillo fusionado, los cuales inhiben la adhesion de leucocitos mediada por vla-4, composiciones farmaceuticas, el uso de las mismas para la manufactura de un medicamento y un metodo para fijar vla-4 en una muestra biologica |
| CA2357781A1 (fr) | 1999-01-22 | 2000-07-27 | Elan Pharmaceuticals, Inc. | Composes inhibant l'adhesion leucocytaire provoquee par vla-4 |
| JP2003519697A (ja) * | 1999-12-28 | 2003-06-24 | ファイザー・プロダクツ・インク | 炎症性疾患、自己免疫疾患および呼吸器疾患の処置に有用な非ペプチド系のｖｌａ−４依存性細胞結合阻害薬 |
-
2000
- 2000-12-15 JP JP2001551869A patent/JP2003519697A/ja not_active Withdrawn
- 2000-12-15 NZ NZ518886A patent/NZ518886A/en unknown
- 2000-12-15 EA EA200200619A patent/EA004673B1/ru not_active IP Right Cessation
- 2000-12-15 EP EP00983429A patent/EP1244656A1/fr not_active Withdrawn
- 2000-12-15 YU YU41202A patent/YU41202A/sh unknown
- 2000-12-15 SK SK869-2002A patent/SK8692002A3/sk not_active Application Discontinuation
- 2000-12-15 AP APAP/P/2002/002565A patent/AP2002002565A0/en unknown
- 2000-12-15 OA OA1200200193A patent/OA12126A/en unknown
- 2000-12-15 CN CN00817813A patent/CN1413210A/zh active Pending
- 2000-12-15 CZ CZ20022072A patent/CZ20022072A3/cs unknown
- 2000-12-15 PL PL00357109A patent/PL357109A1/xx not_active Application Discontinuation
- 2000-12-15 HU HU0203897A patent/HUP0203897A3/hu unknown
- 2000-12-15 WO PCT/IB2000/001893 patent/WO2001051487A1/fr not_active Application Discontinuation
- 2000-12-15 IL IL14975800A patent/IL149758A0/xx unknown
- 2000-12-15 KR KR1020027008400A patent/KR20020067050A/ko not_active Application Discontinuation
- 2000-12-15 EE EEP200200372A patent/EE200200372A/xx unknown
- 2000-12-15 BR BR0016818-1A patent/BR0016818A/pt not_active IP Right Cessation
- 2000-12-15 TR TR2002/01668T patent/TR200201668T2/xx unknown
- 2000-12-15 AU AU20183/01A patent/AU2018301A/en not_active Abandoned
- 2000-12-15 CA CA002396087A patent/CA2396087A1/fr not_active Abandoned
- 2000-12-21 US US09/747,246 patent/US20020049236A1/en not_active Abandoned
- 2000-12-22 SV SV2000000246A patent/SV2002000246A/es unknown
- 2000-12-26 TN TNTNSN00256A patent/TNSN00256A1/fr unknown
- 2000-12-27 GT GT200000226A patent/GT200000226A/es unknown
- 2000-12-27 CO CO00097880A patent/CO5261616A1/es unknown
- 2000-12-27 AR ARP000106961A patent/AR029216A1/es not_active Application Discontinuation
- 2000-12-28 PE PE2000001411A patent/PE20010987A1/es not_active Application Discontinuation
- 2000-12-28 UY UY26512A patent/UY26512A1/es not_active Application Discontinuation
- 2000-12-28 PA PA20008509301A patent/PA8509301A1/es unknown
-
2002
- 2002-05-14 IS IS6382A patent/IS6382A/is unknown
- 2002-06-12 US US10/171,286 patent/US6667331B2/en not_active Expired - Fee Related
- 2002-06-12 US US10/170,289 patent/US6668527B2/en not_active Expired - Fee Related
- 2002-06-14 CR CR6682A patent/CR6682A/es not_active Application Discontinuation
- 2002-06-24 BG BG106867A patent/BG106867A/xx unknown
- 2002-06-24 MA MA26709A patent/MA26861A1/fr unknown
- 2002-06-26 ZA ZA200205142A patent/ZA200205142B/en unknown
- 2002-06-26 NO NO20023085A patent/NO20023085L/no not_active Application Discontinuation
-
2003
- 2003-11-05 US US10/702,539 patent/US6903128B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| OA12126A (en) | Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune,and respiratory diseases. | |
| US11065226B2 (en) | Combination comprising EP4 antagonist and immune checkpoint inhibitor | |
| KR101981880B1 (ko) | 치환된 다환성 피리돈 유도체 및 그의 프로드러그 | |
| ES2626457T3 (es) | Derivados de fluoro-piridinona útiles como agentes antibacterianos | |
| AU2018298733B2 (en) | Fused-ring derivative having MGAT2 inhibitory activity | |
| RU2008116581A (ru) | Сульфонамидные производные, как активаторы гликокиназы, применимые для лечения диабета типа 2 | |
| IL189069A0 (en) | Piperidine and piperazine derivatives as p2x3 antagonists | |
| MY141245A (en) | Macrocylic inhibitors of hepatitis c virus | |
| JP2008530099A5 (fr) | ||
| KR20170082637A (ko) | 단백질 키나아제 억제제로서의 6-아미노-7-바이사이클로-7-데아자-퓨린 유도체 | |
| RU2007148504A (ru) | Индановые производные в качестве модуляторов ионных каналов | |
| CA2785338A1 (fr) | Composes a base de n-(1h-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide substitue utiles en tant qu'inhibiteurs de cfms | |
| CO5251463A1 (es) | Compuestos heterociclicos y composicion farmaceutica que coniene dichos compuestos | |
| NZ600260A (en) | Heteroaromatic phenylimidazole derivatives as pde10a enzyme inhibitors | |
| CA2798222A1 (fr) | Pyrazolopyridines en tant qu'inhibiteurs de la kinase lrrk2 | |
| MX2009010491A (es) | Derivado heterociclico de 5 miembros y su uso para propositos medicos. | |
| KR20230012522A (ko) | 이미다졸 3-옥시드 유도체 기반의 acss2 억제제 및 이의 사용 방법 | |
| KR20190049916A (ko) | 치환된 다환성 피리돈 유도체 및 그의 프로드러그 | |
| JP2006509842A5 (fr) | ||
| AU2005247610A1 (en) | Substituted thiazoleacetic as crth2 ligands | |
| JP7530510B2 (ja) | Ｒｎａヘリカーゼｄｈｘ３３を阻害する多環式化合物及びその応用 | |
| TW200635593A (en) | Pyridyl-substituted spiro-hydantoin crystalline forms and process | |
| JP6858252B2 (ja) | ラパマイシンシグナル伝達経路阻害剤のメカニズム標的、及びその治療応用 | |
| US11993613B2 (en) | Thiazolo[5,4-b]pyridine MALT-1 inhibitors | |
| CN107814795B (zh) | 作为urat1抑制剂的化合物 |